Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies

NCT06528301 is registered in ClinicalTrials.gov with Umoja Biopharma as lead sponsor.

NCT NCT06528301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06528301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-label Study of UB-VV111 in Combination With Rapamycin in Relapsed/Refractory (R/R) CD19+ B-cell Malignancies
Lead sponsor
Umoja Biopharma
Phase
Phase 1
Overall status
Recruiting
Start date
March 10, 2025
Completion date
March 31, 2029
Enrollment
106 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), lymphoma, b-cell, lymphoma, large b-cell, diffuse (dlbcl), lymphoma, non-hodgkin (nhl)